Evaluation and Validation of New Biomarkers by Mass Spectrometry
NCT ID: NCT01025973
Last Updated: 2018-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
99 participants
OBSERVATIONAL
2009-10-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Test for Fetal Malformations
NCT02965287
Gestational Diabetes Mellitus and Neurodevelopment in Newborns
NCT02779452
Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring
NCT01490372
Measuring hCG Levels in Pregnant Women
NCT02763176
Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester
NCT02990767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetes Mellitus
Patients with type 1, type 2 or gestational diabetes mellitus
No interventions assigned to this group
Normal pregnancy
Patient without diabetes mellitus
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 or more
* 24 weeks of gestation or more
* Type 1, type 2 or gestational diabetes mellitus for group 1
* Without diabetes for group 2.
For newborn:
* 37 weeks of gestation or more
* Birth weight 2500 g or more
Exclusion Criteria
1 Day
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean-Luc Ardilouze
Endocrinologist, researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Luc Ardilouze, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Université de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de recherche clinique Etienne-Le Bel du CHUS
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dupont FO, Hivert MF, Allard C, Menard J, Perron P, Bouchard L, Robitaille J, Pasquier JC, Auray-Blais C, Ardilouze JL. Glycation of fetal hemoglobin reflects hyperglycemia exposure in utero. Diabetes Care. 2014 Oct;37(10):2830-3. doi: 10.2337/dc14-0549. Epub 2014 Jul 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.